Physician profile
Naresh Mori
NPI 1629281282
$8,215.62
in general payments reported to CMS, 2019-2025
45 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $246 · 2021: $1,219 · 2022: $1,215 · 2023: $1,393 · 2024: $1,333 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059 · Travel and Lodging: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.92 |
| Travel and Lodging | $667.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,042.05 | 2024-2025 | Igt Devices Undivided, Coronary Other, (Bq9) Coronary Ivus |
| Boston Scientific Corporation | $905.48 | 2019-2025 | Avvigo Guidance System, Varithena Administration Pack |
| Abbott Laboratories | $641.46 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Peripheral, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $474.54 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Edwards Lifesciences Corporation | $427.19 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $372.85 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $301.59 | 2021-2025 | |
| Penumbra, INC. | $284.86 | 2022 | |
| Teleflex LLC | $277.51 | 2023 | Guideliner |
| Abiomed | $272.91 | 2021-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $270.08 | 2021-2025 | |
| Cardiovascular Systems INC. | $262.23 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $255.66 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $223.91 | 2019-2024 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $220.96 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.12 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $164.07 | 2021-2025 | Winrevair |
| Scpharmaceuticals INC. | $152.89 | 2024 | |
| Atricure, INC. | $149.86 | 2021-2023 | |
| Biotronik INC. | $144.56 | 2019 | |
| Inspire Medical Systems, INC. | $140.32 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.31 | 2021-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $123.18 | 2024 | Arcalyst |
| Novo Nordisk INC | $121.14 | 2025 | Ozempic |
| Cardiva Medical, INC. | $99.41 | 2021-2022 | |
| Organogenesis INC. | $78.96 | 2025 | Via Matrix |
| Pfizer INC. | $70.13 | 2019-2022 | |
| Cvrx, INC. | $53.86 | 2024-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $50.21 | 2019-2022 | |
| Tactile Systems Technology INC | $48.75 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Lexicon Pharmaceuticals, INC. | $46.77 | 2024 | |
| Amgen INC. | $34.52 | 2022-2023 | Repatha |
| Kestra Medical Technology Services, INC. | $33.43 | 2024 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $29.66 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.32 | 2023 | Injectafer |
| Jazz Pharmaceuticals INC. | $19.23 | 2020 | |
| Terumo Medical Corporation | $18.75 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.69 | 2025 | Onpattro |
| Cleerly, INC. | $15.90 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Chiesi USA, INC. | $15.27 | 2020 | |
| Bard Peripheral Vascular, INC. | $13.11 | 2023 | Venclose Maven Catheter |
| Gilead Sciences, INC. | $10.82 | 2019 | |
| Thrombolex, INC. | $9.10 | 2024 | Bashir Endovascular Catheter |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Mori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.